What is Langaware?
Langaware is a pioneering company that leverages AI technology to revolutionize cognitive and behavioral health diagnostics. By utilizing speech analysis and proprietary voice and speech biomarkers, LANGaware provides early and objective detection of conditions, enabling more effective treatments, reducing healthcare burdens, and improving overall well-being. The company's vision is to transform the healthcare industry by seamlessly integrating AI-driven diagnostic tools and empowering healthcare professionals with valuable insights for personalized care.
How much funding has Langaware raised?
Langaware has raised a total of $2.1M across 1 funding round:
Angel/Seed
$2.1M
Angel/Seed (2023): $2.1M with participation from Eleven Ventures and Metavallon VC
Key Investors in Langaware
Eleven Ventures
Eleven Ventures is an investment firm that likely focuses on early-stage technology companies, potentially with an interest in disruptive AI applications.
Metavallon VC
Metavallon VC is a venture capital firm that typically invests in innovative startups, possibly with a specialization in technology or deep tech sectors.
What's next for Langaware?
The recent major strategic investment positions Langaware for accelerated growth and market expansion. This capital infusion is expected to fuel further development of its AI-driven diagnostic tools, enhance its proprietary voice and speech biomarker technology, and broaden its reach within the healthcare industry. The company's focus on early and objective detection of cognitive and behavioral health conditions aligns with a growing demand for precision medicine and proactive healthcare solutions, suggesting a trajectory towards becoming a key player in AI-powered health diagnostics.
See full Langaware company page
